Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — Synthetic biology, the industry built around using back-end technologies to engineer the life sciences, has long prided itself on having a quirky, countercultural ethos — and having more fun than those stuffy suits in biotech and pharma. It was just two years ago, after all, that a biohacker CRISPR’d himself on stage at the industry’s big annual conference.

Now, though, the industry is trying to establish its footing here in a town with a culture utterly unlike its own.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.